JPRN-jRCT2080225345招募中2 期
A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination with Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
ONO PHARMACEUTICAL CO., LTD.0 个研究点目标入组 59 人开始时间: 2020年8月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
- •2. Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or
- •investigator-assessed clinical benefit
排除标准
- •1. Participant judged to be incapable of providing consent for reasons such as concurrent dementia
- •2. Participant judged by the investigator to be inappropriate as participants of this study
研究者
相似试验
进行中（未招募）
1 期
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myelomaMultiple MyelomaEUCTR2015-001564-19-NLSecura Bio, Inc.240
已完成
2 期
A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agentsPatient with Relapsed or Relapsed-and-refractory Multiple MyelomaC90.0MMLBCTR2019010183SecuraBio9
进行中（未招募）
1 期
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myelomaMultiple MyelomaEUCTR2015-001564-19-BEovartis Pharma Services AG240
进行中（未招募）
1 期
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2015-001564-19-DEovartis Pharma Services AG240
进行中（未招募）
1 期
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2015-001564-19-CZovartis Pharma Services AG240